NCT04207697

Study to Assess the Safety and Effectiveness of Beltavac® Polymerized With Cat Dander

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 34 (actual)
• Sponsor: Probelte Pharma S.L.U. · Industry
• Sex: All
• Age: 12 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Non-interventional Study to Assess the Safety and Effectiveness Profile of a SCIT Therapy With Beltavac® Polymerized With Cat Dander in allergic patients

Detailed description

This prospective open multi-centre non-interventional study assess the safety and effectiveness profile of the subcutaneous allergen-specific immunotherapy with Beltavac® Polymerized with cat dander allergic patients (children and adults) in routine medical care. Patients receive a rush schedule administration every month for a year. They attend at least 5 study visits to inform about the adverse reactions, the self reported symptoms and the medication intake.

Conditions

• Rhinoconjunctivitis With or Without Allergic Asthma

Interventions

Type	Name	Description
BIOLOGICAL	Beltavac® Polymerized with cat dander	Adminstration of Beltavac® Polymerized with cat dander according to the routine clinical practice

Timeline

• Start date: 2019-12-01
• Primary completion: 2023-02-09
• Completion: 2023-02-09
• First posted: 2019-12-23
• Last updated: 2023-05-11

Locations

7 sites across 1 country: Spain